ArticleScientific reports2025
Hock immunization, a refined alternative for developing experimental autoimmune myasthenia gravis (EAMG) in mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental autoimmune myasthenia gravis (EAMG) is an active-immunization model that was first discovered by coincidence when rabbits injected with purified acetylcholine receptor for neuromuscular junction physiology studies, suddenly developed muscle weakness. In mice, this model typically involves bilateral subcutaneous injections of purified torpedo acetylcholine receptor (tAChR) in the hind footpads and the scapular regions, followed by one or two booster immunizations in the thighs and over the scapulas. However, footpad injections can cause severe discomfort and progressive debilitation. Hock immunization has shown to be a viable alternative in other models, offering comparable efficacy without impairing mobility caused by inflammation, thus reducing discomfort. To investigate the use of hock immunization in the mouse EAMG model, 7-week-old female C57BL6/6J (B6) mice were bilaterally injected over the scapulas and either in the hocks or footpads for the primary immunization. All animals received a booster immunization 4 weeks later, following standard guidelines. Inverted mesh measurements demonstrated that tAChR-immunized animals whether receiving hock or footpad injections, exhibited similar muscle weakness. This weakness correlated with reduced body weight, which reached statistical significance, only in the hock-immunized group. tAChR antibodies were detectable in both groups 4 weeks after primary immunization and continue raising until the end of the experiment. Additionally, tAChR immunized mice required significantly less curare to induce a decremental response of compound muscle action potentials. Notably, hock-immunized mice displayed consistent mechanical sensitivity over time, which was significantly lower compared to footpad-immunized mice. In conclusion, hock-immunization is a refined and effective alternative for developing the EAMG mouse model. It results in similar disease incidence and severity while minimizing immunization-related discomfort compared to the standard footpad method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.